department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

DEFERASIROX · pharmadog

pharmadog
drugs
DEFERASIROX

drug

patient view →

DEFERASIROX

Marketedupdated 2mo ago

by Reddy US Therapeutics Inc

Approved

community read0 votes

all catalysts(7)

approval · 7

DEFERASIROX — FDA approval

DEFERASIROX — FDA approval

DEFERASIROX — FDA approval

DEFERASIROX — FDA approval

DEFERASIROX — FDA approval

DEFERASIROX — FDA approval

DEFERASIROX — FDA approval

News(0)

no news has mentioned this drug yet

brand

DEFERASIROX

generic

DEFERASIROX

indication

Iron Poisoning

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 21, 2034

~8.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Nov 21, 2034compositionUS 9283209
Nov 21, 2034compositionUS 9283209
Nov 21, 2034compositionUS 9283209

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 5

tagApproval14 co-mentions · 7 sources
drugdeferasirox ODT7 co-mentions · 7 sources
drugJadenu7 co-mentions · 7 sources
companyActavis Elizabeth LLC7 co-mentions · 7 sources
tagSmall Molecule7 co-mentions · 7 sources

Trials studying DEFERASIROX

phase2Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agentscompletedn=39
phase2Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)terminatedn=45
phase2Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overloadcompletedn=224
phase2Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndromewithdrawn
phase4Pilot Study for Patients With Poor Response to Deferasiroxcompletedn=15
phase2The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Studycompletedn=20